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Abnormalities of CD4+CD25+Foxp3+ regulatory T cells 
(Tregs) probably contribute to T- and B-cell hyperactivity 
in systemic lupus erythematosus (SLE), but reports on 
numbers and function of these cells in this autoimmune 
disease have been contradictory. Studies on circulating 
CD4+ cells in SLE which express Foxp3, the transcription 
factor that generates these cells, have been inconsistent. 
Various groups have reported decreased, normal, or even 
increased numbers. Another problem is that, in humans, 
Foxp3 cannot be used as a marker of Tregs as activated 
CD4+ non-Tregs can transiently express Foxp3. Finally, 
although CD4+ cells that stain brightly for CD25 are 
Tregs, many CD4+Foxp3+ cells in human SLE are CD25low
or CD25–, and their identity is poorly deﬁ  ned. Two groups 
that reported increased percentages of CD4+CD25–
Foxp3+ cells in SLE have recently tried to characterize 
these cells but reached diﬀ  erent conclusions. A report by 
Yang and colleagues [1] was recently pub  lished in this 
journal and another by Bonelli and colleagues [2] was 
published elsewhere. Here, we discuss the essence of the 
controversy and approaches to resolve it. A more 
complete review of Tregs in SLE has also been published 
in this journal [3].
Th   e report by Yang and colleagues [1] was preceded by 
one in which this group studied subjects with untreated 
new-onset SLE and reported increased percentages of 
CD4+CD25–Foxp3+ cells that were also CD127low  [4]. 
Diﬀ  erences in the intensity of CD127 staining are useful 
to distinguish CD4+ Tregs from CD127bright non-Tregs [5] 
and suggested that the CD25–Foxp3+ cells were Tregs. 
However, this group also reported that the prevalence of 
these cells positively correlated with the titer of anti-
double-stranded DNA antibodies and that these cells 
decreased in most patients with active lupus after 
eﬀ  ective treatment [4]. Th  is ﬁ  nding suggested that the 
CD25–Foxp3+ cells were previously activated non-Tregs. 
Because of these conﬂ  icting observations, they conducted 
a new study, and the report by Yang and colleagues [1] 
was published in a recent issue of this journal.
Th   ese workers again studied new-onset SLE and found 
that the phenotype of CD4+CD25–Foxp3+ cells diﬀ  ered 
from that of typical Tregs. Th  ese  CD25–Foxp3+ cells also 
produced more interleukin-2 (IL-2) and other cytokines 
than CD25highFoxp3+ cells did. Studies investigating the 
value of CD127 as a surrogate marker of Foxp3 revealed 
that although most CD25–Foxp3+ cells were CD127dim or 
CD127–, only 9% of CD25–CD127low/– cells were Foxp3+. 
Th  erefore, the authors concluded that CD127 is not an 
appropriate marker for intracellular Foxp3 in CD4+CD25–
cells. Studies of suppressor function in vitro revealed that 
the CD25–CD127dim/– subset completely lacked suppres-
sive activity. By contrast, CD25dimCD127low/– cells suppressed 
T-cell proliferation though not as well as the 
CD25highCD127low/– subset. Th  us, they concluded that 
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Various abnormalities in CD4+CD25+ regulatory T cells 
(Tregs) in systemic lupus erythematosus (SLE) include 
increased Foxp3+ cells that are CD25 negative. Barring 
methodological technical factors, these cells could be 
atypical Tregs or activated non-Treg CD4+ cells that 
express Foxp3. Two groups have reached opposite 
conclusions that could possibly refl  ect the subjects 
studied. One group studied untreated new-onset 
SLE and suggested that these T cells were mostly 
CD25–Foxp3+ non-Tregs. The other group studied 
patients with long-standing disease and suggested 
that these cells are mostly dysfunctional Tregs. A third 
group reported increased Foxp3+CD4+CD25dim rather 
than CD25– cells in active SLE and these were also 
non-Tregs. Thus, it is likely that not all Foxp3+ T cells in 
SLE have protective suppressive activity.
© 2010 BioMed Central Ltd
Identity of mysterious CD4+CD25–Foxp3+ cells in 
systemic lupus erythematosus
David A Horwitz*
See related research by Yang et al., http://arthritis-research.com/content/11/5/R153
EDITORIAL
*Correspondence: dhorwitz@usc.edu 
Division of Rheumatology, Department of Medicine, University of Southern 
California, Keck School of Medicine, 2011 Zonal Avenue, HMR 711, Los Angeles, CA 
90033, USA
Horwitz Arthritis Research & Therapy 2010, 12:101 
http://arthritis-research.com/content/12/1/101
© 2010 BioMed Central LtdCD4+CD25–Foxp3+ in untreated new-onset lupus patients 
lacked the phenotype and functional activity of Tregs.
Instead of studying new-onset subjects, Bonelli and 
colleagues [2] studied patients with SLE, rheumatoid 
arthritis, or systemic sclerosis who were drawn from the 
authors’ outpatient clinics and found increased percen-
tages of CD4+CD25–Foxp3+ cells in SLE only. Th  eir 
phenotypic proﬁ  le included CD127low and was consistent 
with the cells being Tregs rather than T-eﬀ  ector cells. 
Th  ese workers isolated CD4+CD25–CD127– cells by 
ﬂ   uorescence-activated cell sorting and found that the 
cells contained up to 53% Foxp3+ T cells. Functional 
studies revealed that these cells suppressed T-cell proli-
feration but not production of interferon-gamma, a 
suppressor T-cell abnormality also described in rheuma-
toid arthritis [6]. Because of phenotypic and functional 
similarities to typical Tregs, the authors concluded that 
CD4+CD25–Foxp3+ T cells in SLE were dysfunctional 
Tregs.
Th   us, whereas Yang and colleagues [1] concluded that 
most CD4+CD25–Foxp3+ cells in SLE are probably 
previously activated conventional T cells, Bonelli and 
colleagues [2] suggested that they are dysfunctional 
Tregs. Th  e strengths of the argument of Yang and 
colleagues are the phenotypic diﬀ  erences, the presence of 
cells producing IL-2 and other cytokines, the lack of 
suppressive activity, and the fact that fewer than 10% of 
CD4+CD25–CD127low/– cells expressed Foxp3. Th  e  strengths 
of the argument of Bonelli and colleagues [2] include the 
fact that more than 30% of CD4+CD25–CD127low/– cells 
expressed Foxp3, the lack of proliferative potential, the 
lack of cytokine-producing cells, and the ability to suppress 
T-cell proliferation in vitro. Th  e  diﬀ  erent conclusions of 
the two groups can possibly be explained by the groups of 
lupus patients studied. One studied untreated newly 
diagnosed subjects, whereas the other studied treated 
individuals with less active disease. It is certainly possible 
that the CD25–Foxp3+ cells reﬂ  ect diﬀ  erent populations, 
depending upon when the subjects were studied.
A remaining important question is the reason why 
these cells are CD25–. Both Tregs and activated CD4+ 
cells generally express CD25. Miyara and colleagues [7] 
recently characterized CD4+Foxp3+ cells and divided 
them into three distinctive populations based upon 
CD45RA expression and intensity of CD25 staining. 
Th  ese included naïve CD45RA+CD25moderateFoxp3lo Treg 
resting precursor cells that, when activated, become 
CD45RA–CD25highFoxp3hi Treg eﬀ  ector cells. Th  e third 
population consisted of CD45RA–CD25dimFoxp3lo non-
Tregs. Interestingly, in patients with active disease, these 
workers reported increased proportions of CD4+Foxp3+ 
non-Tregs which decreased as the disease became less 
active. Th   ey did not ﬁ  nd CD4+CD25–Foxp3+ cells in SLE. 
Th  e  CD4+CD25– cells described by Bonelli and colleagues 
[2] were mostly Foxp3lo. Th   erefore, if these cells were also 
CD45RA–, they would be similar to the CD4+Foxp3+ non-
Tregs described by Miyara and colleagues [7] and the 
diﬀ  erence between the two studies would be the staining 
intensity of the anti-CD25 conjugate used.
Another method to distinguish CD4+Foxp3+ Tregs 
from non-Tregs would be to examine the stability of 
Foxp3 expressed by these cells in culture. As stated above, 
Foxp3 expressed by Tregs is relatively stable whereas that 
of non-Tregs is not [8]. Finally, activated Tregs display 
membrane-bound transforming growth factor-beta [9] 
and LAP (latency-associated protein) [10]. To convin-
cingly show that a given subset has regulatory rather than 
eﬀ  ector function, one should demonstrate suppressor cell 
activity  in vivo in an animal model as described by 
Hippen and colleagues [11] with human cord blood 
CD4+CD25+ cells.
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